{"downloaded": true, "htmlmade": false, "full": {"id": "29769208", "source": "MED", "pmid": "29769208", "pmcid": "PMC6125184", "fullTextIdList": {"fullTextId": "PMC6125184"}, "doi": "10.1158/1078-0432.ccr-18-0449", "title": "Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.", "authorString": "Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC.", "authorList": {"author": [{"fullName": "Davies JK", "firstName": "Jeff K", "lastName": "Davies", "initials": "JK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK."}}}, {"fullName": "Brennan LL", "firstName": "Lisa L", "lastName": "Brennan", "initials": "LL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Wingard JR", "firstName": "John R", "lastName": "Wingard", "initials": "JR", "authorId": {"@type": "ORCID", "#text": "0000-0001-7478-5398"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Florida College of Medicine, Gainesville, Florida."}}}, {"fullName": "Cogle CR", "firstName": "Christopher R", "lastName": "Cogle", "initials": "CR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Florida College of Medicine, Gainesville, Florida."}}}, {"fullName": "Kapoor N", "firstName": "Neena", "lastName": "Kapoor", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Shah AJ", "firstName": "Ami J", "lastName": "Shah", "initials": "AJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford University School of Medicine, Stanford, California."}}}, {"fullName": "Dey BR", "firstName": "Bimalangshu R", "lastName": "Dey", "initials": "BR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts."}}}, {"fullName": "Spitzer TR", "firstName": "Thomas R", "lastName": "Spitzer", "initials": "TR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts."}}}, {"fullName": "de Lima M", "firstName": "Marcos", "lastName": "de Lima", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Bone Marrow Transplant, University Hospital Cleveland Medical Center, Cleveland, Ohio."}}}, {"fullName": "Cooper LJ", "firstName": "Laurence J", "lastName": "Cooper", "initials": "LJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}}}, {"fullName": "Thall PF", "firstName": "Peter F", "lastName": "Thall", "initials": "PF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}}}, {"fullName": "Champlin RE", "firstName": "Richard E", "lastName": "Champlin", "initials": "RE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Stem Cell Transplant and Cellular Therapies, The University of Texas MD Anderson Cancer Center, Houston, Texas."}}}, {"fullName": "Nadler LM", "firstName": "Lee M", "lastName": "Nadler", "initials": "LM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Guinan EC", "firstName": "Eva C", "lastName": "Guinan", "initials": "EC", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. eva_guinan@dfci.harvard.edu."}, {"affiliation": "Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts."}]}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0001-7478-5398"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "17", "volume": "24", "journalIssueId": "2723151", "dateOfPublication": "2018 Sep", "monthOfPublication": "9", "yearOfPublication": "2018", "printPublicationDate": "2018-09-01", "journal": {"title": "Clinical cancer research : an official journal of the American Association for Cancer Research", "ISOAbbreviation": "Clin Cancer Res", "medlineAbbreviation": "Clin Cancer Res", "NLMid": "9502500", "ISSN": "1078-0432", "ESSN": "1557-3265"}}, "pubYear": "2018", "pageInfo": "4098-4109", "abstractText": "Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative treatment for many hematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T cells is a simple approach to rebuild immunity while limiting GvHD after haploidentical HSCT, but the optimal T-cell dose and impact on immune reconstitution remain unknown.Patients and Methods: We performed a multicenter phase I trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT. The primary aim was feasibility and safety with secondary aims of assessing the less frequently addressed issue of impact on immune reconstitution.Results: Nineteen patients with high-risk acute leukemia or myelodysplasia were enrolled. Engraftment occurred in 18 of 19 patients (95%). Pre-aDLI, 12 patients (63%) had bacteremia, nine of 17 at-risk patients (53%) reactivated CMV, and one developed acute GvHD. Sixteen patients received aDLI at dose levels 1 (103 T cells/kg, n = 4), 2 (104, n = 8), and 3 (105, n = 4). After aDLI, five patients developed clinically significant acute GvHD, and four of 14 at-risk patients (29%) reactivated CMV. T-cell recovery was significantly greater, and functional virus- and tumor-associated antigen-specific T cells were detectable earlier in patients receiving dose level 2 or 3 versus dose level 1/no aDLI. Alloanergization of donor cells expanded the CD4+ T-regulatory cell frequency within aDLI, which increased further in vivo without impeding expansion of virus- and tumor-associated antigen-specific T cells.Conclusions: These data demonstrate safety and a potential role for aDLI in contributing to immune reconstitution and expanding tolerogenic regulatory T cells in vivo after CD34-selected myeloablative haploidentical HSCT. Clin Cancer Res; 24(17); 4098-109. \u00a92018 AACR.", "affiliation": "Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "R21 CA137645", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U19 CA100265", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "G0902269", "agency": "Medical Research Council", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Lymphocytes", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "T-Lymphocytes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "CD4-Positive T-Lymphocytes", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Myelodysplastic Syndromes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Graft vs Host Disease", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Myeloablative Agonists", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antigens, CD34", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocyte Transfusion"}, {"majorTopic_YN": "N", "descriptorName": "Transplantation Conditioning"}, {"majorTopic_YN": "Y", "descriptorName": "Hematopoietic Stem Cell Transplantation"}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Homologous"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Tissue Donors"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Immunity, Innate", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Haploidentical"}]}, "chemicalList": {"chemical": [{"name": "Antigens, CD34", "registryNumber": "0"}, {"name": "Myeloablative Agonists", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.CCR-18-0449"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6125184"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6125184?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.ccr-18-0449"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "2", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS968656", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-11-08", "dateOfCreation": "2018-05-18", "firstIndexDate": "2018-05-17", "fullTextReceivedDate": "2020-10-27", "dateOfRevision": "2019-11-08", "electronicPublicationDate": "2018-05-16", "firstPublicationDate": "2018-05-16", "embargoDate": "2019-03-01"}, "abstract": "Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative treatment for many hematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T cells is a simple approach to rebuild immunity while limiting GvHD after haploidentical HSCT, but the optimal T-cell dose and impact on immune reconstitution remain unknown.Patients and Methods: We performed a multicenter phase I trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT. The primary aim was feasibility and safety with secondary aims of assessing the less frequently addressed issue of impact on immune reconstitution.Results: Nineteen patients with high-risk acute leukemia or myelodysplasia were enrolled. Engraftment occurred in 18 of 19 patients (95%). Pre-aDLI, 12 patients (63%) had bacteremia, nine of 17 at-risk patients (53%) reactivated CMV, and one developed acute GvHD. Sixteen patients received aDLI at dose levels 1 (103 T cells/kg, n = 4), 2 (104, n = 8), and 3 (105, n = 4). After aDLI, five patients developed clinically significant acute GvHD, and four of 14 at-risk patients (29%) reactivated CMV. T-cell recovery was significantly greater, and functional virus- and tumor-associated antigen-specific T cells were detectable earlier in patients receiving dose level 2 or 3 versus dose level 1/no aDLI. Alloanergization of donor cells expanded the CD4+ T-regulatory cell frequency within aDLI, which increased further in vivo without impeding expansion of virus- and tumor-associated antigen-specific T cells.Conclusions: These data demonstrate safety and a potential role for aDLI in contributing to immune reconstitution and expanding tolerogenic regulatory T cells in vivo after CD34-selected myeloablative haploidentical HSCT. Clin Cancer Res; 24(17); 4098-109. \u00a92018 AACR.", "journaltitle": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authorinfo": ["Davies JK", "Brennan LL", "Wingard JR", "Cogle CR", "Kapoor N", "Shah AJ", "Dey BR", "Spitzer TR", "de Lima M", "Cooper LJ", "Thall PF", "Champlin RE", "Nadler LM", "Guinan EC"], "title": "Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation."}